{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:44:14Z","timestamp":1793843054360,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jacl.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T20:26:41Z","timestamp":1532118401000},"page":"1313-1323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size"],"prefix":"10.1016","volume":"12","author":[{"given":"Sotirios","family":"Tsimikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.07.003_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2017.01.017","article-title":"Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms","volume":"69","author":"Verbeek","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib4","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.07.003_bib5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) over >\/=1.5 years (from the phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.07.003_bib8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.07.003_bib9","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.07.003_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ecl.2015.09.003","article-title":"Lipoprotein apheresis","volume":"45","author":"Moriarty","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacl.2018.07.003_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.plipres.2017.09.001","article-title":"The renaissance of lipoprotein(a): brave new world for preventive cardiology?","volume":"68","author":"Ellis","year":"2017","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.jacl.2018.07.003_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacl.2010.07.002","article-title":"Management of Lp(a)","volume":"4","author":"Brown","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.07.003_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.07.003_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2018.07.003_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1399-0004.1997.tb04357.x","article-title":"LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients","volume":"52","author":"Kronenberg","year":"1997","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacl.2018.07.003_bib17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC international reference reagent for lipoprotein(a) for immunoassay--Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacl.2018.07.003_bib18","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2018.07.003_bib19","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.07.003_bib20","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.07.003_bib21","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/clinchem\/32.8.1484","article-title":"Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B","volume":"32","author":"Young","year":"1986","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2018.07.003_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.07.003_bib23","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.07.003_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.07.003_bib25","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1194\/jlr.M005769","article-title":"Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet","volume":"51","author":"Faghihnia","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.07.003_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/01.ATV.0000118012.64932.f4","article-title":"Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a)","volume":"24","author":"Silaste","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2018.07.003_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2017.03.036","article-title":"Effect of spontaneous changes in dietary components and lipoprotein(a) levels: data from the Brisighella heart study","volume":"262","author":"Fogacci","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2018.07.003_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2017.10.020","article-title":"Changes in lipoprotein(a) following bariatric surgery","volume":"197","author":"Lin","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2018.07.003_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.07.003_bib30","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.07.003_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u201cLDL-C\u201d\u00a0= LDL-C\u00a0+ Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2018.07.003_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.07.003_bib33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","article-title":"Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study","volume":"52","author":"Lamon-Fava","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.07.003_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cca.2014.10.013","article-title":"Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis","volume":"439","author":"Guadagno","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2018.07.003_bib35","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2018.07.003_bib36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacl.2016.09.012","article-title":"Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.07.003_bib37","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1373\/clinchem.2016.270751","article-title":"Evaluation of lipoprotein(a) electrophoretic and immunoassay methods in discriminating risk of calcific aortic valve disease and incident coronary heart disease: the multi-ethnic study of atherosclerosis","volume":"63","author":"Cao","year":"2017","journal-title":"Clin Chem"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418303027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418303027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:28:58Z","timestamp":1604644138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418303027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1933287418303027"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.07.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}